Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Read

Showing results (721-730 of 723) with videos related to

Pageof 73
Sort By:
You have reached the last page of results.This site can display upto 723 results.
Nature|June 14, 2013
Pan genome of the phytoplankton Emiliania underpins its global distributionBetsy A Read, Jessica Kegel, Mary J Klute, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Genome-wide discovery reveals 30 loci for choroidal thickness and uncovers potential causal links with angle-closure glaucomaSamantha Sze-Yee Lee, Carol A Wang, Victor A de Vries, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 73

Showing results (721-730 of 723) with videos related to

Sort By:
Pageof 73
You have reached the last page of results.This site can display upto 723 results.
Nature|June 14, 2013
Pan genome of the phytoplankton Emiliania underpins its global distributionBetsy A Read, Jessica Kegel, Mary J Klute, et al.
Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
Genome-wide discovery reveals 30 loci for choroidal thickness and uncovers potential causal links with angle-closure glaucomaSamantha Sze-Yee Lee, Carol A Wang, Victor A de Vries, et al.
The Lancet. Respiratory Medicine|July 30, 2016
Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trialDonald P Tashkin, Michael D Roth, Philip J Clements, et al.
Pageof 73